Showing 3801-3810 of 5559 results for "".
- Lithera Changes Name to Neothetics, Inc.https://practicaldermatology.com/news/20140812-lithera_changes_name_to_neothetics_inc/2459146/In a move the company says is intended to stregthen its positioning as a clinical stage, specialty pharmaceutical company developing novel therapeutics for the aesthetics market, Lithera has changed its name to Neothetics, Inc. President and CEO of Neothetics George Mahaffey said, "Our ne
- Envy Medical and Libbs Farmaceutical Plan Strategic Marketing, Sales and Distribution Agreement For Brazilhttps://practicaldermatology.com/news/20140723-envy_medical_and_libbs_farmaceutical_plan_strategic_marketing_sales_and_distribution_agreement_for_brazil/2459159/Envy Medical and Libbs Farmaceutical made an agreement to manufacture, market and sell Envy's proprietary Lumixyl® Brightening Creme throughout the country of Brazil. This represents significant agreement with Libbs, a leader in the sales and supply of pharmaceutical products, it also rep
- Merz Signs Licensing Agreement with Brickell Biotech for Development of a Novel Retinoid Therapyhttps://practicaldermatology.com/news/20140702-merz_signs_licensing_agreement_with_brickell_biotech_for_development_of_a_novel_retinoid_therapy/2459182/Merz North America, Inc. signed an agreement with Brickell Biotech, Inc. granting Merz an exclusive North American license with certain additional international rights to develop and commercialize, a completely novel retinoid compound for the treatment of skin conditions respons
- AAD Announces Donation of Melanoma Exposed Program from Bristol-Myers Squibbhttps://practicaldermatology.com/news/20140609-aad_announces_donation_of_melanoma_exposed_program_from_bristol-myers_squibb/2459214/Bristol-Myers Squibb donated its Melanoma Exposed™ program to the American Academy of Dermatology (AAD). The donation, provided through a charitable grant, will be used to increase public awareness of skin cancer—including melanoma, the deadliest form of skin cancer—and expand t
- Valeant Pharmaceuticals To Sell Filler And Toxin Assets To Nestle For $1.4 Billionhttps://practicaldermatology.com/news/20140528-valeant_pharmaceuticals_to_sell_filler_and_toxin_assets_to_nestle_for_14_billion/2459228/Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that it has entered into an agreement with Nestle S.A. to sell all rights to Restylane, Perlane, Emervel, Sculptra, and Dysport owned or held by Valeant for $1.4 billion in cash. Nestle expects to complete its acquis
- Nuvo Research Announces Collaboration to Develop Topical Dermatology Productshttps://practicaldermatology.com/news/20140423-nuvo_research_announces_collaboration_to_develop_topical_dermatology_products/2459258/Nuvo Research Inc. is collaborating with Ferndale Laboratories, Inc. and a leading Contract Research Organization (CRO) with significant dermatology experience to develop two topical dermatology products based on Nuvo's patented Multiplexe
- Valeant Pharmaceuticals Donates $250,000 to The National Coalition Against Domestic Violencehttps://practicaldermatology.com/news/20140317-valeant_pharmaceuticals_donates_250000_to_the_national_coalition_against_domestic_violence/2459314/Valeant Pharmaceuticals North America, LLC donated $250,000 to the National Coalition Again
- Doctors Issue New Treatment Guidelines for Skin Abscesses Caused By MRSAhttps://practicaldermatology.com/news/20140317-doctors_issue_new_treatment_guidelines_for_skin_abscesses_caused_by_mrsa/2459315/It has been more than 10 years since the clinical battle began with community-acquired methicillin-resistant Staphylococcus aureus (MRSA), and doctors are still grappling with how to diagnose, treat and prevent this virulent form of staph infection, which is immune to man
- Foamix, Ltd. Will Present Phase II Results for Topical Minocycline at Upcoming Conferencehttps://practicaldermatology.com/news/20140227-foamix_ltd_will_present_phase_2_results_for_topical_minocycline_at_upcoming_conference/2459328/Foamix will present the successful results from its Phase II clinical trials with topical minocycline for acne and impetigo at the 34th Annual Cowen & Company Health Care Conference. The pharmaceutical company, which focuses on the development of patented topical foams for de
- Eclipse Sun Launches New Line of Sun Protective Clothing for Babies and Kidshttps://practicaldermatology.com/news/20140220-eclipse_sun_launches_new_line_of_sun_protective_clothing_for_babies_and_kids/2459336/Eclipse Sun Products announced the introduction of its new line of sun protective clothing made especially for babies and kids. The